再生元制药 2024年度报告

REGENERON BY THE NUMBERS 14 medicines approvedin the United Statesor other countries 12 approvals for additionalindications or populationsfor existing products in theUnited States, EuropeanUnion, and Japan in 2024 ~40 product candidatesin clinical development 100K+eligible patients given~$3.4B* worth ofmedicine at no costthrough our products’patient assistanceprograms in 2024 ~50countries withclinical trials ~3M exomes sequencedto date by RegeneronGenetics Center® 15.1K+Regeneron colleaguesworldwide at2024 year-end ~3.2Mstudents supportedby Regeneron STEMinitiatives since 2020 52%employee volunteerismrate in 2024 FORM 10-K UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549FORM 10-K (Mark One) ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the fiscal year ended December 31, 2024OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from __________ to __________ Commission File Number: 000-19034 REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter)New York13-3444607(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)777 Old Saw Mill River Road Tarrytown, New York 10591-6707(Address of principal executive offices, including zip code)(914) 847-7000(Registrant's telephone number, including area code)Securities registered pursuant to Section 12(b) of the Act:Title of each classTrading SymbolName of each exchange on which registeredCommon Stock - par value $.001 per shareREGNNASDAQ Global Select MarketSecurities registered pursuant to section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes☒No☐ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.Yes☐No☒ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and(2) has been subject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant toRule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant wasrequired to submit such files).Yes☒ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or anemerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company"in Rule 12b-2 of the Exchange Act. Accelerated filer☐Non-accelerated filer☐Smaller reporting company☐Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any newor revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internalcontrol over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm thatprepared or issued its audit report. If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in thefiling reflect the correction of an error to previously issued financial statements. Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation receivedby any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). The aggregate market value of the voting and non-voting common stock held by non-affiliates of the registrant was $113.8 billion, computed by reference tothe closing sales price of the stock on NASDAQ on June 28, 2024, the last trading day of the registrant's most recently completed second fiscal quarter. Forpurposes of this calculation only, the registrant has assumed that all of its directors and executive officers, and no other persons, are its affiliates. Thisdetermination of affiliate status is not necessarily a determination for other purposes. The number of shares outstanding of each of the registrant's classes of common stock as of January 23, 2025: DOCUMENTS INCORPORATED BY REFERENCE Specified portions of the